586 related articles for article (PubMed ID: 30499151)
1. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Randon G; Kook MC; An JY; Grabsch HI; Prisciandaro M; Nichetti F; Noh SH; Sohn TS; Kim S; Wotherspoon A; Morano F; Cunningham D; Lee J; Cheong JH; Smyth EC; Pietrantonio F
Eur J Cancer; 2024 May; 203():114043. PubMed ID: 38598921
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
5. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
7. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
[TBL] [Abstract][Full Text] [Related]
8. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.
An JY; Kim H; Cheong JH; Hyung WJ; Kim H; Noh SH
Int J Cancer; 2012 Jul; 131(2):505-11. PubMed ID: 21898388
[TBL] [Abstract][Full Text] [Related]
10. Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.
Jiang D; Shu C; Zhang W; Sun L; Zhang M; He Y; Owen G; Jin W; He D; Deng X; Liu X
Virchows Arch; 2021 Feb; 478(2):231-240. PubMed ID: 32588133
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
12. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
13. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
14. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients.
Hiltner T; Kohlruss M; Herz AL; Lorenzen S; Novotny A; Hapfelmeier A; Jesinghaus M; Slotta-Huspenina J; Sisic L; Gaida MM; Weichert W; Ott K; Keller G
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7651-7662. PubMed ID: 37000259
[TBL] [Abstract][Full Text] [Related]
16. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.
Kim SY; Choi YY; An JY; Shin HB; Jo A; Choi H; Seo SH; Bang HJ; Cheong JH; Hyung WJ; Noh SH
Int J Cancer; 2015 Aug; 137(4):819-25. PubMed ID: 25614197
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy.
Du C; Zhao J; Xue W; Dou F; Gu J
Histopathology; 2013 Apr; 62(5):723-30. PubMed ID: 23425253
[TBL] [Abstract][Full Text] [Related]
18. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability in solitary and sporadic gastric cancer.
Perez RO; Jacob CE; D'Ottaviano FL; Alvarenga C; Ribeiro AS; Ribeiro U; Bresciani CJ; Zilberstein B; Krieger JE; Habr-Gama A; Gama-Rodrigues JJ
Rev Hosp Clin Fac Med Sao Paulo; 2004 Oct; 59(5):279-85. PubMed ID: 15543400
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite Instability Analysis in Gastric Carcinomas of Moroccan Patients.
Nshizirungu JP; Bennis S; Mellouki I; Benajah DA; Lahmidani N; El Bouhaddoutti H; Ibn Majdoub K; Ibrahimi SA; Pires Celeiro S; Viana-Pereira M; Manuel Reis R
Genet Test Mol Biomarkers; 2021 Feb; 25(2):116-123. PubMed ID: 33596142
[No Abstract] [Full Text] [Related]
[Next] [New Search]
